Tylicki L - Search Results

1

Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology.

Stompór T, Adamczak M, Kurnatowska I, Naumnik B, Nowicki M, Tylicki L, Winiarska A, Krajewska M. Stompór T, et al. Among authors: tylicki l. J Clin Med. 2023 Aug 9;12(16):5184. doi: 10.3390/jcm12165184. J Clin Med. 2023. PMID: 37629226 Free PMC article. Review.

2

Effects of N-acetylcysteine on angiotensin-converting enzyme plasma activity in patients with chronic kidney diseases.

Tylicki L, Renke M, Rutkowski P, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Tylicki L, et al. Blood Purif. 2008;26(4):354. doi: 10.1159/000133431. Epub 2008 May 19. Blood Purif. 2008. PMID: 18487879 Free article. No abstract available.

3

High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.

Renke M, Tylicki L, Knap N, Rutkowski P, Neuwelt A, Petranyuk A, Larczynski W, Wozniak M, Rutkowski B. Renke M, et al. Among authors: tylicki l. Nephrol Dial Transplant. 2009 Feb;24(2):689-90. doi: 10.1093/ndt/gfn665. Epub 2008 Dec 2. Nephrol Dial Transplant. 2009. PMID: 19054799 Clinical Trial. No abstract available.

4

Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.

Tylicki L, Rutkowski P, Renke M, Rutkowski B. Tylicki L, et al. Kidney Int. 2007 Nov;72(9):1164-5. doi: 10.1038/sj.ki.5002511. Kidney Int. 2007. PMID: 17943159 Free article. Clinical Trial. No abstract available.

5

Atorvastatin attenuates oxidative stress in patients with chronic kidney disease.

Renke M, Knap N, Tylicki L, Rutkowski P, Neuwelt A, Larczynski W, Wozniak M, Rutkowski B. Renke M, et al. Among authors: tylicki l. Med Sci Monit. 2010 Mar;16(3):LE3-3. Med Sci Monit. 2010. PMID: 20190691 Clinical Trial. No abstract available.

6

Ozone therapy seems to be safe, but is it really clinically effective?

Tylicki L, Rutkowski B. Tylicki L, et al. Int J Artif Organs. 2004 Aug;27(8):731-2; author reply 733. doi: 10.1177/039139880402700813. Int J Artif Organs. 2004. PMID: 15478546 No abstract available.

7

Spironolactone attenuates oxidative stress in patients with chronic kidney disease.

Renke M, Tylicki L, Knap N, Rutkowski P, Neuwelt A, Larczynski W, Wozniak M, Rutkowski B. Renke M, et al. Among authors: tylicki l. Hypertension. 2008 Nov;52(5):e132-3; author reply e134. doi: 10.1161/HYPERTENSIONAHA.108.120568. Epub 2008 Sep 29. Hypertension. 2008. PMID: 18824658 Clinical Trial. No abstract available.

8

Metabolic disturbances as strong determinator of kidney injury in essential hypertension.

Tylicki L, Rutkowski B. Tylicki L, et al. J Hypertens. 2005 Jul;23(7):1433-4. doi: 10.1097/01.hjh.0000173529.18921.a5. J Hypertens. 2005. PMID: 15942468 No abstract available.

9

Ozonetherapy in a dialyzed patient with calcific uremic arteriolopathy.

Biedunkiewicz B, Tylicki L, Lichodziejewska-Niemierko M, Liberek T, Rutkowski B. Biedunkiewicz B, et al. Among authors: tylicki l. Kidney Int. 2003 Jul;64(1):367-8. doi: 10.1046/j.1523-1755.2003.00089.x. Kidney Int. 2003. PMID: 12787437 Free article. No abstract available.

10

[Cyclophosphamide pulse therapy in patients with primary glomerulonephritis].

Rutkowski B, Wielgosz A, Manitius J, Bułło B, Kowalewska J, Tylicki L, Roszkiewicz A. Rutkowski B, et al. Among authors: tylicki l. Przegl Lek. 2000;57(11):624-7. Przegl Lek. 2000. PMID: 11293209 Clinical Trial. Polish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page